In AR-positive bladder cancer cells, DHT could activate the epidermal growth factor receptor (EGFR)/ERBB2/ERK pathway in the presence of the epidermal growth factor (EGF). This evidence concerns the gene ERBB2 and urinary bladder carcinoma.